Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2006 3
2007 1
2008 1
2009 3
2010 10
2011 6
2012 5
2013 8
2014 18
2015 20
2016 34
2017 31
2018 25
2019 19
2020 18
2021 17
2022 14
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27119512

215 results

Results by year

Filters applied: . Clear all
Page 1
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O, Vacher S, Lecerf C, Jeannot E, Klijanienko J, Berger F, Hoffmann C, Calugaru V, Badois N, Chilles A, Lesnik M, Krhili S, Bieche I, Le Tourneau C, Kamal M. Leblanc O, et al. Cancer Biol Med. 2020 Feb 15;17(1):208-217. doi: 10.20892/j.issn.2095-3941.2019.0153. Cancer Biol Med. 2020. PMID: 32296588 Free PMC article.
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M. Toledo RA, et al. Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311. Oncotarget. 2017. PMID: 27852040 Free PMC article. Clinical Trial.
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, Sacco A, Rachiglio AM, Martinelli E, Rizzi D, Pisconti S, Biglietto M, Bordonaro R, Troiani T, Latiano TP, Giuliani F, Leo S, Rinaldi A, Maiello E, Ciardiello F; CAPRI-GOIM Investigators. Normanno N, et al. Ann Oncol. 2018 Jan 1;29(1):112-118. doi: 10.1093/annonc/mdx417. Ann Oncol. 2018. PMID: 28950295 Free article. Clinical Trial.
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. Chung CH, et al. Ann Oncol. 2014 Nov;25(11):2230-2236. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31. Ann Oncol. 2014. PMID: 25081901 Free PMC article. Clinical Trial.
215 results